Tirzepatide NEW
| Price | Get Latest Price | ||
| Package | 1box | 10box | 100box |
| Min. Order: | 1box |
| Supply Ability: | 10000 |
| Update Time: | 2025-01-07 |
| Related documents: | COA |
Product Details
| Product Name: Tirzepatide | CAS No.: 2023788-19-2 |
| Min. Order: 1box | Purity: 99.99% |
| Supply Ability: 10000 | Release date: 2025/01/07 |
factory directly supply semaglutide 910463-68-2 Tirzepatide 2023788-19-2 Retatrutide 2381089-83-2 MotsC ,Nad+,Kpv, Reta 15,Tesa/ipa 4 kits or tesa 4 and ipa 4,Bpc,Tb500,Ghkcu,Ss31,Slupp332,Cagriwith fast delivery 4-7 days to USA Canada UK Australia
Product Description
Research Peptide Semaglutide Tirzepatide Retatrutide... etc API
| Items Name | Tirzepatide API (Research Purpose Only) | Costomize | 2mg 5mg 10mg 15mg 20mg 30mg 60mg |
| CAS Code | 2023788-19-2 | Vial size | 3ml/5ml/10ml |
| Raw Materials | White Powder | Type | Lyophilized process, vaccum seal |
| Package | White Paper Box | GMP | Fully GMP standard operation |
| Test Method | HPLC, MS | Filling Vial | over filled each vial |
| Cap color | Multiple colors customize | Payment Way | SWIFT, ACH, Fedwire, Bank Wire, Wise, Revolut, |
| Purity Content | 99-100% | Reship Policy | Yes |
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials. Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety.
Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide allows for once-weekly dosing. Tirzepatide was approved by the F/DA on May 13, 2022, under the brand name MO/UNJ/ARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor agonist for this indication. Later, it was approved under a different brand name ZEP/BO/UND on November 8, 2023, for the chronic weight management in adults with obesity or overweight with at least one weight-related condition. On September 15, 2022, tirzepatide was also approved by the European Commission.
Contact information
+86 13363081079/+86 13363081709
Whatsapp / telegram
nancy:+86 13363081079
sherry:+86 13363081709
mailbox:13363081079@163.com
Company Profile Introduction
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2025-01-09 | |
| $10.00/1KG |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2025-01-07 | |
| $130.00/10G |
VIP1Y
|
Hebei Shengyang Water Conservancy Engineering Co., Ltd.
|
2025-01-06 | |
| $5.00/1Box |
VIP1Y
|
Hebei Jiafan Trading Company Limited
|
2024-12-19 | |
| $1.00/1BOX |
VIP1Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2024-12-17 | |
| $0.00/1g |
VIP1Y
|
Wuhan Circle Star Chem-medical Technology Co.,Ltd
|
2024-12-17 | |
| $0.00/1g |
VIP1Y
|
Zhangzhou Sinobioway Peptide Co.,Ltd.
|
2024-12-17 | |
| $35.71/1Box |
VIP1Y
|
American HealthyMorph LLC
|
2024-12-13 | |
| $20.00/1kg |
Shaanxi Franta Biotechnology Co., Ltd
|
2024-12-06 | ||
| $1.00/1gram |
VIP6Y
|
Shanghai Longyu Biotechnology Co., Ltd.
|
2024-11-26 |
China
- Since: 2020-08-28
- Address: Room 201, Unit 2, Comprehensive Service Building, No.11 Xinxu Impression City, Fengyi Road, Shunhua
INQUIRY